At DCAT 2025, Quotient Sciences showcased how using a fully integrated service provider can help optimize drug development.
In a video interview held just prior to the event, Helen Baker, Director of Formulation Design, discussed the benefits of having clinical, late-stage, and regulatory processes under one provider for benefits including better knowledge sharing and a more secure supply chain.
"A huge advantage of [having services under one umbrella] is that you cut out the white space that you often see between services as you move between them, as you go through the development process." Baker says in highlighting the Quotient Sciences Translational Pharmaceutics® platform—a disruptive approach to drug development that redefines the complementary, interconnected relationship between drug product design, supply and clinical testing.
"There's a single product manager … managing everything from start to finish. And it just simplifies the whole process, reduces that risk [of] what we already know is a very lengthy, costly and risky development process." she continued.